Monitoring the action of redox-directed cancer therapeutics using a human peroxiredoxin-2-based probe
Name
s41467-018-05557-y.pdf
Size
1.26 MB
Format
Adobe PDF
Checksum (MD5)
cbd0a8c9f701085002080cc012e35fbb
Author(s)
Langford, Troy F.
Huang, Beijing Kara
Lim, Joseph B.
Moon, Sun Jin
Sikes Johnson, Hadley
Date Issued
August 2018
Journal
Nature Communications
Publisher
Nature Publishing Group
Citation
Langford, Troy F., Beijing K. Huang, Joseph B. Lim, Sun Jin Moon, and Hadley D. Sikes. “Monitoring the Action of Redox-Directed Cancer Therapeutics Using a Human Peroxiredoxin-2-Based Probe.” Nature Communications 9, no. 1 (August 7, 2018). © 2018 The Authors
Version
Final published version
Abstract
Redox cancer therapeutics target the increased reliance on intracellular antioxidant systems and enhanced susceptibility to oxidant-induced stress of some cancer cells compared to normal cells. Many of these therapeutics are thought to perturb intracellular levels of the oxidant hydrogen peroxide (H[subscript 2]O[subscript 2]), a signaling molecule that modulates a number of different processes in human cells. However, fluorescent probes for this species remain limited in their ability to detect the small perturbations induced during successful treatments. We report a fluorescent sensor based upon human peroxiredoxin-2, which acts as the natural indicator of small H[subscript 2]O[subscript 2] fluctuations in human cells. The new probe reveals peroxide-induced oxidation in human cells below the detection limit of current probes, as well as peroxiredoxin-2 oxidation caused by two different redox cancer therapeutics in living cells. This capability will be useful in elucidating the mechanism of current redox-based therapeutics and in developing new ones.
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Terms of Use
Creative Commons Attribution 4.0 International license
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/s41467-018-05557-y
